CA2371231A1 - Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel - Google Patents
Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel Download PDFInfo
- Publication number
- CA2371231A1 CA2371231A1 CA002371231A CA2371231A CA2371231A1 CA 2371231 A1 CA2371231 A1 CA 2371231A1 CA 002371231 A CA002371231 A CA 002371231A CA 2371231 A CA2371231 A CA 2371231A CA 2371231 A1 CA2371231 A1 CA 2371231A1
- Authority
- CA
- Canada
- Prior art keywords
- aspirin
- pharmaceutical composition
- clopidogrel
- hydrogenosulphate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 title claims abstract description 67
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 67
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 title claims abstract description 67
- 229960003009 clopidogrel Drugs 0.000 title claims abstract description 67
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 claims description 47
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 239000007903 gelatin capsule Substances 0.000 claims description 8
- 206010002388 Angina unstable Diseases 0.000 claims description 6
- 208000007814 Unstable Angina Diseases 0.000 claims description 6
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 6
- 230000007170 pathology Effects 0.000 claims description 6
- 230000009424 thromboembolic effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010061216 Infarction Diseases 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 208000007718 Stable Angina Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 238000013171 endarterectomy Methods 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 230000007574 infarction Effects 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 230000002537 thrombolytic effect Effects 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000002744 anti-aggregatory effect Effects 0.000 abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- 239000008119 colloidal silica Substances 0.000 description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 23
- 239000004359 castor oil Substances 0.000 description 23
- 235000019438 castor oil Nutrition 0.000 description 23
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 239000000470 constituent Substances 0.000 description 20
- 229920002261 Corn starch Polymers 0.000 description 18
- 229930195725 Mannitol Natural products 0.000 description 18
- 239000008120 corn starch Substances 0.000 description 18
- 239000000594 mannitol Substances 0.000 description 18
- 229960001855 mannitol Drugs 0.000 description 18
- 235000010355 mannitol Nutrition 0.000 description 18
- 238000002156 mixing Methods 0.000 description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 14
- 239000008108 microcrystalline cellulose Substances 0.000 description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 description 14
- 238000005469 granulation Methods 0.000 description 12
- 230000003179 granulation Effects 0.000 description 12
- 229960001375 lactose Drugs 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 229960004977 anhydrous lactose Drugs 0.000 description 5
- 239000012943 hotmelt Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 229960003511 macrogol Drugs 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition pharmaceutique se présentant sous une forme galénique unitaire contenant une association de principes actifs à activité antiagrégant plaquettaire constituée d'acide acétylsalicylique et d'hydrogénosulfate de clopidogrel.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9905497A FR2792836B3 (fr) | 1999-04-30 | 1999-04-30 | Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel |
| FR99/05497 | 1999-04-30 | ||
| PCT/FR2000/001086 WO2000066130A1 (fr) | 1999-04-30 | 2000-04-25 | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2371231A1 true CA2371231A1 (fr) | 2000-11-09 |
Family
ID=9545071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002371231A Abandoned CA2371231A1 (fr) | 1999-04-30 | 2000-04-25 | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1178809A1 (fr) |
| JP (1) | JP2002543137A (fr) |
| KR (1) | KR20020005735A (fr) |
| CN (1) | CN1359294A (fr) |
| AR (1) | AR023789A1 (fr) |
| AU (1) | AU4303600A (fr) |
| BR (1) | BR0010194A (fr) |
| CA (1) | CA2371231A1 (fr) |
| CZ (1) | CZ20013887A3 (fr) |
| EA (1) | EA200100959A1 (fr) |
| EE (1) | EE200100559A (fr) |
| FR (1) | FR2792836B3 (fr) |
| HK (1) | HK1041823A1 (fr) |
| HU (1) | HUP0202329A2 (fr) |
| IL (1) | IL145648A0 (fr) |
| IS (1) | IS6084A (fr) |
| MX (1) | MXPA01011071A (fr) |
| NO (1) | NO20015295L (fr) |
| NZ (1) | NZ514248A (fr) |
| PL (1) | PL351923A1 (fr) |
| SK (1) | SK15542001A3 (fr) |
| TR (1) | TR200103039T2 (fr) |
| UY (1) | UY26131A1 (fr) |
| WO (1) | WO2000066130A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100341506C (zh) | 2000-12-25 | 2007-10-10 | 三共株式会社 | 含有阿斯匹林的药用组合物 |
| RU2180848C1 (ru) * | 2001-01-30 | 2002-03-27 | Плотников Марк Борисович | Средство с антиагрегантной и гемореологической активностью |
| US6767913B2 (en) | 2001-12-18 | 2004-07-27 | Teva Pharmaceutical Industries Ltd. | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms |
| US7074928B2 (en) | 2002-01-11 | 2006-07-11 | Teva Pharmaceutical Industries, Ltd. | Polymorphs of clopidogrel hydrogensulfate |
| IL166593A0 (en) | 2002-08-02 | 2006-01-15 | Racemization and enantiomer separation of clopidogrel | |
| US6800759B2 (en) | 2002-08-02 | 2004-10-05 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
| JP4917255B2 (ja) * | 2003-10-16 | 2012-04-18 | 第一三共ヘルスケア株式会社 | サリチル酸類含有経口組成物 |
| WO2005070464A2 (fr) * | 2004-01-21 | 2005-08-04 | Biofarma Ilac Sanayi Ve Ticaret A.S. | Formulation de comprimes de bisulfate de clopidogrel |
| US20070003615A1 (en) * | 2005-06-13 | 2007-01-04 | Elan Pharma International Limited | Nanoparticulate clopidogrel and aspirin combination formulations |
| KR20070009851A (ko) * | 2005-07-14 | 2007-01-19 | 씨제이 주식회사 | 클로피도그렐 황산수소염 함유 약학 조성물 |
| EP1926736A4 (fr) * | 2005-09-21 | 2010-08-25 | Chong Kun Dang Pharm Corp | Nouveau complexe de resinate de s-clopidogrel et procede pour le produire |
| KR20070044323A (ko) * | 2005-10-24 | 2007-04-27 | 에스케이케미칼주식회사 | 보관안정성이 개선된 클로피도그렐 황산수소염 함유 경구용제제 |
| US20100145053A1 (en) * | 2006-04-05 | 2010-06-10 | Cadila Healthcare Limited | Modified release clopidogrel formulation |
| EP1900358A1 (fr) * | 2006-09-16 | 2008-03-19 | Cimex Pharma AG | Formulations pharmaceutiques contenant du clopidogrel |
| HUP0600839A3 (en) * | 2006-11-14 | 2008-09-29 | Egis Gyogyszergyar Nyrt | Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof |
| EP2255797A4 (fr) * | 2008-02-22 | 2011-09-07 | Hanall Biopharma Co Ltd | Préparation composite |
| CN101695496A (zh) * | 2009-10-15 | 2010-04-21 | 苏春华 | 一种含有三氟柳和氯吡格雷的药物组合物 |
| JP2013032289A (ja) * | 2009-10-28 | 2013-02-14 | Daiichi Sankyo Co Ltd | ワックス安定製剤 |
| RU2484820C2 (ru) * | 2011-02-24 | 2013-06-20 | Общество с ограниченной ответственностью "Озон" | Комбинированное лекарственное средство, являющееся ингибитором агрегации тромбоцитов |
| KR101675501B1 (ko) | 2011-11-02 | 2016-11-14 | 한국유나이티드제약 주식회사 | 클로피도그렐 및 아스피린의 복합제제 |
| CN102406938A (zh) * | 2011-11-29 | 2012-04-11 | 北京阜康仁生物制药科技有限公司 | 一种抗血栓的药物组合物 |
| JP6004524B2 (ja) * | 2012-07-11 | 2016-10-12 | 大原薬品工業株式会社 | クロピドグレル硫酸塩含有錠剤の製造方法 |
| WO2015015062A1 (fr) * | 2013-08-02 | 2015-02-05 | Sanofi | Comprime pharmaceutique comprenant de l'acide acetylsalicylique et du clopidogrel |
| CN104434932B (zh) * | 2014-12-18 | 2017-05-24 | 成都苑东生物制药股份有限公司 | 一种硫酸氢氯吡格雷阿司匹林片药物组合物及其制备方法 |
| WO2017037741A1 (fr) * | 2015-09-02 | 2017-03-09 | Sun Pharmaceutical Industries Ltd | Forme posologique solide et compacte à base d'aspirine et de clopidogrel |
| CN115737578A (zh) * | 2022-11-23 | 2023-03-07 | 石家庄四药有限公司 | 一种硫酸氢氯吡格雷阿司匹林复方片及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| US5576328A (en) * | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
| FR2744918B1 (fr) | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| FR2779726B1 (fr) | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
-
1999
- 1999-04-30 FR FR9905497A patent/FR2792836B3/fr not_active Expired - Fee Related
-
2000
- 2000-04-25 JP JP2000615014A patent/JP2002543137A/ja not_active Withdrawn
- 2000-04-25 HU HU0202329A patent/HUP0202329A2/hu unknown
- 2000-04-25 IL IL14564800A patent/IL145648A0/xx unknown
- 2000-04-25 EE EEP200100559A patent/EE200100559A/xx unknown
- 2000-04-25 KR KR1020017013830A patent/KR20020005735A/ko not_active Withdrawn
- 2000-04-25 EA EA200100959A patent/EA200100959A1/ru unknown
- 2000-04-25 AU AU43036/00A patent/AU4303600A/en not_active Abandoned
- 2000-04-25 HK HK02103639.9A patent/HK1041823A1/zh unknown
- 2000-04-25 NZ NZ514248A patent/NZ514248A/xx unknown
- 2000-04-25 TR TR2001/03039T patent/TR200103039T2/xx unknown
- 2000-04-25 CN CN00807001A patent/CN1359294A/zh active Pending
- 2000-04-25 SK SK1554-2001A patent/SK15542001A3/sk unknown
- 2000-04-25 CZ CZ20013887A patent/CZ20013887A3/cs unknown
- 2000-04-25 CA CA002371231A patent/CA2371231A1/fr not_active Abandoned
- 2000-04-25 WO PCT/FR2000/001086 patent/WO2000066130A1/fr not_active Ceased
- 2000-04-25 EP EP00922737A patent/EP1178809A1/fr not_active Withdrawn
- 2000-04-25 MX MXPA01011071A patent/MXPA01011071A/es unknown
- 2000-04-25 BR BR0010194-0A patent/BR0010194A/pt not_active Application Discontinuation
- 2000-04-25 PL PL00351923A patent/PL351923A1/xx not_active Application Discontinuation
- 2000-04-28 AR ARP000102020A patent/AR023789A1/es unknown
- 2000-04-28 UY UY26131A patent/UY26131A1/es not_active Application Discontinuation
-
2001
- 2001-09-25 IS IS6084A patent/IS6084A/is unknown
- 2001-10-29 NO NO20015295A patent/NO20015295L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020005735A (ko) | 2002-01-17 |
| AR023789A1 (es) | 2002-09-04 |
| NZ514248A (en) | 2003-06-30 |
| FR2792836B3 (fr) | 2001-07-27 |
| CZ20013887A3 (cs) | 2002-02-13 |
| EP1178809A1 (fr) | 2002-02-13 |
| IL145648A0 (en) | 2002-06-30 |
| EE200100559A (et) | 2003-02-17 |
| NO20015295L (no) | 2001-12-21 |
| PL351923A1 (en) | 2003-06-30 |
| EA200100959A1 (ru) | 2002-06-27 |
| AU4303600A (en) | 2000-11-17 |
| BR0010194A (pt) | 2002-02-13 |
| MXPA01011071A (es) | 2002-07-22 |
| HUP0202329A2 (en) | 2002-10-28 |
| FR2792836A1 (fr) | 2000-11-03 |
| CN1359294A (zh) | 2002-07-17 |
| HK1041823A1 (zh) | 2002-07-26 |
| JP2002543137A (ja) | 2002-12-17 |
| SK15542001A3 (sk) | 2002-02-05 |
| UY26131A1 (es) | 2000-12-29 |
| IS6084A (is) | 2001-09-25 |
| WO2000066130A1 (fr) | 2000-11-09 |
| NO20015295D0 (no) | 2001-10-29 |
| TR200103039T2 (tr) | 2002-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2371231A1 (fr) | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel | |
| JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
| AU737738B2 (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
| US5814339A (en) | Film coated tablet of paracetamol and domperidone | |
| JP5702305B2 (ja) | 有核型の口腔内崩壊錠 | |
| JP6051317B2 (ja) | テモゾロミドを含む安定性が改善された薬剤学的組成物およびその製造方法 | |
| PL200957B1 (pl) | Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej | |
| ZA200309289B (en) | Oxcarbazepine dosage forms. | |
| CA2804358A1 (fr) | Compositions pharmaceutiques contenant de la vanoxerine | |
| JP5458096B2 (ja) | 有核型の口腔内崩壊錠 | |
| KR20240145412A (ko) | 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법 | |
| CN114306259A (zh) | 一种丙戊酸钠双层缓释片及其制备方法 | |
| HK1010687B (en) | Film coated tablet of paracetamol and domperidone | |
| HK1031325B (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
| AU2007263016A1 (en) | Oral pharmaceutical composition of a poorly water-soluble active substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |